Categories: News

Delta-8 THC Now Reported by LightLab 3 Cannabis Analyzer

NEW LONDON, N.H., April 29, 2021 /PRNewswire/ — Orange Photonics is pleased to announce that the LightLab 3 Cannabis Analyzer now reports Delta-8 THC (D8-THC), an increasingly popular cannabinoid found in hemp-derived cannabis products. In addition, Orange Photonics is releasing a new Mobile Monitoring feature which gives users the ability to track sample test progress and view results from a smartphone.

LightLab 3 users can now monitor Delta-8 THC levels in cannabis products alongside the 11 other cannabinoids LightLab reports, offering a clear picture of the cannabinoid profile for a particular product. “Product differentiation is a key aspect of a successful cannabis or hemp product line.” says Stephanie McArdle, President of Orange Photonics. “LightLab 3 users have a competitive advantage by leveraging real-time data to drive product value, and support quality, consistency and innovation. Delta-8 THC is a trending cannabinoid; its release is indicative of Orange Photonics’ commitment to keep pace with market developments.”

“Delta-8 THC is challenging even for laboratory testing equipment since it is so similar in structure to D9-THC. Despite LightLab 3’s significantly lower cost and simpler operation, we are pleased to be able to measure Delta-8 THC on the platform.” explains Orange Photonics CTO, Dylan Wilks. “This is possible because our platform is dedicated to cannabis analysis, so it can be optimized in ways that general purpose laboratory equipment cannot. In a sense, LightLab offers the best of both worlds: lab-grade HPLC technology combined with cannabis specific enhancements that make it easy for anyone to use.”

The new Mobile Monitoring feature release gives LightLab 3 users the ability to remotely track testing progress from start to finish from a smart phone. The Mobile Monitoring feature is available on every LightLab 3 Cannabis Analyzer.

To learn more visit www.orangephotonics.com

About Orange Photonics
Founded in 2015, Orange Photonics is based in New Hampshire, USA. LightLab Cannabis Analyzer, is a purpose-built, liquid chromatogram designed for non-technical users. LightLab measures 12+ cannabinoids in 9+ sample types including adult use and hemp cannabis plants and extracted products. LightLab’s Hemp Compliance Module quantifies THC content down to 0.05%, lower than the federal threshold of 0.3%. Orange Photonics’ analytical instrumentation serves the needs of the cannabis industry, counting cultivators, extractors, departments of agriculture, law enforcement, universities, testing laboratories and regulators among its customers.

View original content to download multimedia:http://www.prnewswire.com/news-releases/delta-8-thc-now-reported-by-lightlab-3-cannabis-analyzer-301280388.html

SOURCE Orange Photonics

Staff

Recent Posts

Med Holdings Group, Inc. (FKA Yuka Group, Inc.) Announces Acquisition Of Medsmart Wellness Centers, Inc.

DENVER, CO / ACCESSWIRE / March 22, 2024 / (OTC Pink:YUKA) Med Holdings Group, Inc.…

50 mins ago

GE HealthCare Announces Cash Dividend for First Quarter of 2024

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a…

4 hours ago

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases…

4 hours ago

Smartsheet Names Katie Rooney to Board of Directors

Experienced global CFO adds depth in financial strategy and operating excellence to Smartsheet boardBELLEVUE, Wash.--(BUSINESS…

4 hours ago

The Centers for Medicare & Medicaid Services Revise National Coverage Determination for Stem Cell Transplantation

The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic…

4 hours ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March…

5 hours ago